Increased H-FABP concentrations in nonalcoholic fatty liver disease: Possible marker for subclinical myocardial damage and subclinical atherosclerosis

Herz

Volumn 38, Issue 4, 2013, Pages 417-422

  Basar O ^a   Akbal, E ^b   Koklu S ^b   Tuna, Y ^a   Kocak E ^b   Basar N ^a   Tok, D ^c   Erbis H ^d   Senes M ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^d PAMUKKALE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Carotid intima media thickness; H FABP; Nonalcoholic fatty liver disease; Subclinical atherosclerosis; Subclinical myocardial damage

Indexed keywords

BIOLOGICAL MARKER; FATTY ACID BINDING PROTEIN; GLUCOSE; LIVER ENZYME; PROTEIN H FABP; UNCLASSIFIED DRUG;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; B SCAN; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL; SUBCLINICAL ATHEROSCLEROSIS; SUBCLINICAL MYOCARDIAL DAMAGE;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; FATTY ACID-BINDING PROTEINS; FATTY LIVER; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MYOCARDIAL STUNNING; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 84879076147     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-012-3714-x     Document Type: Article

References (59)

1. Angulo P (2002) Medical progress: nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231
2. Edmison J, McCullough AJ (2007) Pathogenesis of nonalcoholic steatohepatitis: human data. Clin Liver Dis 11:75-104
3. Marchesini G, Brizi M, Bianchi G, Tomassetti S et al (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-1850
4. Polak JF, Pencina MJ, Pencina KM et al (2011) Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 365:213-221
5. O'Leary DH, Polak JF, Kronmal RA et al (1999) Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 340:14-22
6. Salonen JT, Salonen R (1993) Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 87(suppl):II56-II65
7. Chambless LE, Heiss G, Folsom AR et al (1997) Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 146:483-494
8. Salonen R, Salonen JT (1990) Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. Atherosclerosis 81:33-40
9. Fournier NC, Richard MA (1990) Role of fatty acid-binding protein in cardiac fatty acid oxidation. Mol Cell Biochem 98:149-159
10. Pelsers MM, Hermens WT, Glatz JF (2005) Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 352:15-35
11. Adams JE, Trent R, Rawles J (1993) Earliest electrocardiographic evidence of myocardial infarction: implications for thrombolytic treatment. Br Med J 307:409-413
12. Ishii J, Wang JH, Naruse H et al (1997) Serum concentrations of myoglobin vs. human heart-type cytoplasmic fatty acid-binding protein in early detection of acute myocardial infarction. Clin Chem 43:1372-1378
13. Kleine AH, Glatz JFC, Nieuwenhoven FA van et al (1992) Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem 116:155-162
14. Vuilleumier N, Righini M, Perrier A et al (2008) Correlation between cardiac biomarkers and right ventricular enlargement on chest CT in non massive pulmonary embolism. Thromb Res 21:617-624
15. Sugiura T, Takase H, Toriyama T et al (2005) Circulating levels of myocardial proteins predict future deterioration of congestive heart failure. J Card Fail 11:504-509
16. Nagahara D, Nakata T, Hashimoto A et al (2006) Early positive biomarker in relation to myocardial necrosis and impaired fatty acid metabolism in patients presenting with acute chest pain at an emergency room. Circ J 70:419-425
17. Arimoto T, Takeishi Y, Niizeki T et al (2007) Cardiac sympathetic denervation and ongoing myocardial damage for prognosis in early stages of heart failure. J Card Fail 13:34-41
18. Niizeki T, Takeishi Y, Takabatake N et al (2007) Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: effects of age, gender, and physiologic characteristics. Circ J 71:1452-1457
19. Komamura K, Sasaki T, Hanatani A et al (2006) Heart-type fatty acid binding protein is a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy. Heart 92:615-628
20. Wunderlich MT, Hanhoff T, Goertler M et al (2005) Release of brain-type and heart type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol 252:718-724
21. Renaud B, Ngako A (2007) Heart-type fatty acid-binding proteins (H-FABP): a reliable tool for initial risk stratification of pulmonary embolism? Eur Heart J 28:146-157
22. Oktay B, Akbal E, Firat H et al (2008) Evaluation of the relationship between heart type fatty acid binding protein levels and the risk of cardiac damage in patients with obstructive sleep apnea syndrome. Sleep Breath 12:223-228
23. Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J et al (2004) Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics 3:66-72
24. Wada-Isoe K, Imamura K, Kitamaya M et al (2008) Serum heart-fatty acid binding protein levels in patients with Lewy body disease. J Neurol Sci 266:20-24
25. Akbal E, Özbek M, Güneş F et al (2009) Serum heart type fatty acid binding protein levels in metabolic syndrome. Endocrine 36:433-437
26. Karbek B, Özbek M, Bozkurt NC et al (2011) Heart-type fatty acid binding protein (H-FABP): relationship with arterial intima-media thickness and role as diagnostic marker for atherosclerosis in patients with impaired glucose metabolism. Cardiovasc Diabetol 2:10-37
27. Hamaguchi M, Kojima T, Itoh Y et al (2007) The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 12:2708-2715
28. Bhatia LS, Curzen NP, Calder PC et al (2012) Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 33:1190-2000
29. Fraser A, Harris R, Sattar N et al (2007) Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 27:2729-2735
30. Mottillo S, Filion KB, Genest J et al (2010) The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 56:1113-1132
31. Lucero D, Zago V, Lopez GI et al (2011) Pro-inflammatory and atherogenic circulating factors in nonalcoholic fatty liver disease associated to metabolic syndrome. Clin Chim Acta 412:143-147
32. Wong CKL, Burgess MI, Pugh CJ et al (2011) Elevated liver fat in non alcoholic fatty liver disease is associated with impaired myocardial relaxation. J Diabetes 3:202
33. Wong CK, Burgess MI, Irwin A et al (2010) Evidence of diastolic dysfunction in NAFLD: a study using tissue Doppler echocardiography. Diabetologia 53:495-496
34. Seo JM, Park TH, Lee DY et al (2011) Subclinical myocardial dysfunction in metabolic syndrome patients without hypertension. J Cardiovasc Ultrasound 19:134-139
35. Dinh W, Lankisch M, Nickl W et al (2011) Metabolic syndrome with or without diabetes contributes to left ventricular diastolic dysfunction. Acta Cardiol 66:167-174
36. Witteles RM, Fowler MB (2008) Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 51:93-102
37. Tanaka T, Hirota Y, Sohmiya K et al (1991) Nishimura S, Kawamura K. Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem 24:195-201
38. Glatz JF, Kleine AH, Nieuwenhoven FA van et al (1994) Fatty acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans. Br Heart J 71:135-140
39. Setsuta K, Seino Y, Ogawa T et al (2002) Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am J Med 113:717-722
40. Arimoto T, Takeishi Y, Shiga R et al (2005) Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure. J Card Fail 11:56-60
41. Niizeki T, Takeishi Y, Arimoto T et al (2005) Risk stratification using a combination of heart-type fatty acid binding protein and brain natriuretic peptide in patients hospitalized for congestive heart failure. Circ J 69:922-927
42. Niizeki T, Takeishi Y, Arimoto T et al (2005). Serum heart-type fatty acid binding protein predicts cardiac events in elderly patients with chronic heart failure. J Cardiol 46:9-15
43. Niizeki T, Takeishi Y, Arimoto T et al (2007) Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J Card Fail 13:120-127
44. Ohno K, Tsutamoto T, Ishikawa C et al (2004) Relationship between the transcardiac increase of plasma heart-type fatty acid-binding protein and left ventricular remodeling in patients with dilated cardiomyopathy J Am Coll Cardiol 3:1031-1134
45. Morioka N, Shigematsu Y, Hamada M et al (2005) Circulating levels of heart-type fatty acid-binding protein and its relation to thallium-201 perfusion defects in patients with hypertrophic cardiomyopathy. Am J Cardiol 195:1334-1337
46. Lim TK, Lim E, Dwivedi G et al (2008) Normal value of carotid intima-media thickness - a surrogate marker of atherosclerosis: quantitative assessment by B-mode carotid ultrasound. J Am Soc Echocardiogr 21:112-116
47. Raitakari OT, Juonala M, Kähönen M et al (2003) Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 290:2277-2283
48. Tzou WS, Douglas PS, Srinivasan SR et al (2005) Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J Am Coll Cardiol 46:457-463
49. Skilton MR, Moulin P, Serusclat A et al (2007) A comparison of the NCEPATP III, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. Atherosclerosis 190:416-422
50. Czernichow S, Bertrais S, Blacher J et al (2005) Metabolic syndrome in relation to structure and function of large arteries: a predominant effect of blood pressure. A report from the SU.VI.MAX. Vascular Study. Am J Hypertens 18:1154-1160
51. Bertoni AG, Wong ND, Shea S et al (2007) Insulin resistance, metabolic syndrome, and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 30:2951-2956
52. Marchesini G, Bugianesi E, Forlani G et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917-923
53. Rector RS, Thyfault JP, Wei Y et al (2008) Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 14:185-192
54. Kim JH, Kim SY, Jung ES et al (2011) Carotid intima-media thickness is increased not only in non-alcoholic fatty liver disease patients but also in alcoholic Fatty liver patients. Digestion 84:149-155
55. Wong VW, Wong GL, Yip GW et al (2011) Coronary artery disease and cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Gut 60:1721-1727
56. Sun L, Lu SZ (2011) Association between nonalcoholic fatty liver disease and coronary artery disease severity. Chin Med J (Engl) 124:867-872
57. Mohammadi A, Bazazi A, Ghasemi-Rad M et al (2011) Evaluation of atherosclerotic findings in patients with nonalcoholic fatty liver disease. Int J Gen Med 4:717-722
58. Kim D, Choi SY, Park EH et al (2012) Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 56:605-613
59. Kang MK, Yoon H, Seon H et al (2011) Association between nonalcoholic fatty liver disease and subclinical coronary atherosclerosis determined by MDCT. Hepatology 54:1115A-1116A